Patent Armory, Inc. v. Humana, Inc.: Voluntary Dismissal in Call Routing Patent Dispute

Case Overview

The Parties

The Patents at Issue

Five U.S. patents were asserted in this action, covering various aspects of intelligent communication routing and telephony control:

• • US7023979B1 — Covers core telephony and intelligent call routing methodology
• • US7269253B1 — Relates to telephony control systems with intelligent routing capabilities
• • US9456086B1 — Directed to communication routing systems and methods
• • US10237420B1 — Covers advanced communication routing architecture
• • US10491748B1 — Relates to method and system for matching entities in an auction context

Litigation Timeline & Procedural History

The case had a brief but defined lifespan:

The Western District of Texas has historically been a preferred forum for patent assertion entities, offering established patent dockets and experienced judicial infrastructure. The Waco Division in particular gained prominence following the rise of Judge Alan Albright’s patent-friendly scheduling practices, though judicial assignments shift over time.

The case closed at the district court (first instance) level without progressing to claim construction, summary judgment, or trial. Humana had not served an answer or motion for summary judgment prior to dismissal — indicating the litigation resolved before any substantive merits briefing occurred. The 126-day lifespan from filing to closure is consistent with pre-answer resolution patterns in NPE cases, where early negotiations or strategic reassessment precede formal dismissal.

The Verdict & Legal Analysis

Outcome

The case was terminated by **voluntary dismissal with prejudice** pursuant to Federal Rule of Civil Procedure 41(a)(1)(A)(i), filed by Plaintiff on August 5, 2025. The court’s August 6 order confirmed the dismissal as self-effectuating, requiring no judicial action to take effect. Each party was ordered to bear its own costs, expenses, and attorney fees. No damages were assessed, and no injunctive relief was granted.

The with-prejudice designation is legally significant: Patent Armory is permanently barred from reasserting the same claims against Humana on the same patents. This is a complete resolution, not a procedural pause.

Procedural Analysis

Rule 41(a)(1)(A)(i) permits a plaintiff to dismiss without a court order when the opposing party has not yet served an answer or summary judgment motion. The court cited *In re Amerijet International, Inc.*, 785 F.3d 967, 973 (5th Cir. 2015), confirming the self-effectuating nature of such notices. This procedural mechanism is frequently used in patent assertion cases to close matters following settlement negotiations, licensing agreements, or strategic withdrawal — though the specific motivation here was not disclosed in the court record.

Legal Significance

Because the case resolved without a merits ruling, it carries **no direct precedential value** on patent validity, claim construction, or infringement. However, the procedural posture itself is instructive. The early dismissal with prejudice signals that whatever resolution occurred — whether licensing, settlement, or strategic withdrawal — it was conclusive. Patent Armory foreclosed any future litigation path against Humana on these specific claims.

For the asserted patents, particularly the foundational telephony control patents (US7023979B1, US7269253B1), this outcome does not extinguish assertion rights against other defendants. Patent Armory retains the ability to assert the same portfolio against different parties.

Strategic Takeaways

For Patent Holders & Assertion Entities:

Early-stage voluntary dismissal with prejudice sacrifices future assertion rights against a specific defendant. Litigants should ensure that pre-dismissal negotiations have fully addressed portfolio value before filing under Rule 41(a)(1)(A)(i). Structuring licensing agreements to close before formal dismissal is critical to preserving commercial leverage.

For Accused Infringers:

Receiving a patent infringement complaint in the W.D. Tex. does not necessarily require full litigation engagement. Companies should evaluate the plaintiff’s litigation history, patent portfolio strength, and the availability of inter partes review (IPR) challenges at the USPTO as early defensive tools. A prompt freedom-to-operate (FTO) analysis on asserted patents can inform settlement versus defense strategy.

For R&D Teams:

The five asserted patents cover broadly applicable communications routing concepts. Companies operating intelligent call routing, IVR systems, or auction-based lead distribution platforms should conduct FTO reviews against this portfolio — particularly US10491748B1 (entity matching in auction context) and US9456086B1 (communication routing systems) — as they remain active and assertable against other parties.

Industry & Competitive Implications

This case reflects a persistent litigation pattern: NPEs asserting foundational communications patents against large enterprise operators in healthcare, insurance, and financial services — industries that rely extensively on high-volume intelligent telephony infrastructure.

The healthcare sector presents a particularly attractive target profile given its scale of customer communication operations. Humana’s call routing infrastructure, like that of comparable payors, processes millions of member interactions annually, creating high theoretical exposure for per-unit royalty calculations.

From a broader market perspective, the voluntary dismissal without any public settlement disclosure maintains confidentiality around licensing terms — a common outcome in NPE cases where the parties prefer private resolution. This opacity makes portfolio valuation difficult for market observers but is consistent with standard NPE licensing practice.

For competitors and industry peers, the key intelligence from this case is the active assertion posture of the Patent Armory portfolio across telecommunications and healthcare technology intersections. Companies deploying similar routing architectures should monitor this portfolio proactively.

FAQ

What patents were involved in Patent Armory v. Humana?

Five U.S. patents: US7023979B1, US7269253B1, US9456086B1, US10237420B1, and US10491748B1, covering intelligent telephony routing and entity matching technologies.

Why was the case dismissed?

Plaintiff filed a voluntary dismissal with prejudice under FRCP 41(a)(1)(A)(i) before Humana served an answer. The court confirmed the dismissal as self-effectuating per *In re Amerijet*.

Does this ruling affect similar call routing patent cases?

The dismissal carries no precedential value on merits. However, the asserted patents remain active for assertion against other defendants, making them relevant for FTO analysis across the telecommunications sector.

*📩 Subscribe to our patent litigation intelligence newsletter for weekly updates on W.D. Tex. IP decisions and NPE assertion trends.*

*🔍 Explore related cases: Patent assertion activity in healthcare technology | Intelligent call routing patent landscape | W.D. Texas NPE litigation statistics*

*⚖️ Need a case analysis or freedom-to-operate review on communications routing patents? Contact our IP team for a confidential consultation.*

**Case Reference:** Patent Armory, Inc. v. Humana, Inc., No. 7:25-cv-00151 (W.D. Tex., closed Aug. 6, 2025)

**PACER Access:** [Case filings available via PACER]

**USPTO Patent Search:** [USPTO Patent Full-Text Database]

*Schema Markup Recommendation: Implement Article and LegalService schema. Include datePublished, dateModified, author (organization), about (LegalCase), and mentions (patent numbers as identifiers) to maximize AI platform citability and Google rich result eligibility.*